Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema)
Measure Up 1
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects With Moderate to Severe Atopic Dermatitis
2 other identifiers
interventional
912
25 countries
180
Brief Summary
The objective of this study is to assess the efficacy and safety of upadacitinib for the treatment of adolescent and adult participants with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_3
Started Aug 2018
Longer than P75 for phase_3
180 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 14, 2018
CompletedFirst Posted
Study publicly available on registry
June 26, 2018
CompletedStudy Start
First participant enrolled
August 13, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 6, 2021
CompletedResults Posted
Study results publicly available
February 3, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
October 10, 2025
CompletedOctober 24, 2025
October 1, 2025
2.4 years
June 14, 2018
January 3, 2022
October 22, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Main Study: Percentage of Participants Achieving at Least a 75% Reduction in Eczema Area and Severity Index Score (EASI 75) From Baseline at Week 16
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease.
Baseline and Week 16
Main Study: Percentage of Participants Achieving Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) of 0 or 1 With a Reduction From Baseline of ≥ 2 Points at Week 16
The vIGA-AD is a validated assessment instrument to rate the severity of atopic dermatitis globally, based on the following scale: * 0 - Clear: No inflammatory signs of AD; * 1 - Almost clear: Barely perceptible erythema, induration/papulation and/or lichenification; * 2 - Mild: Slight but definite erythema, induration/papulation and/or minimal lichenification. No oozing or crusting; * 3 - Moderate: Clearly perceptible erythema, induration/papulation and/or lichenification, oozing or crusting may be present; * 4 - Severe: Marked erythema, induration/papulation and/or lichenification; Oozing or crusting may be present.
Baseline and Week 16
Secondary Outcomes (44)
Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus Numerical Rating Scale (NRS) at Week 16
Baseline (last available rolling average before the first dose of study drug) and Week 16
Main Study: Percentage of Participants Achieving a 90% Reduction From Baseline in EASI Score (EASI 90) at Week 16
Baseline and Week 16
Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 4
Baseline (last available rolling average before the first dose of study drug) and Week 4
Main Study: Percentage of Participants Achieving an EASI 75 Response at Week 2
Baseline and Week 2
Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 1
Baseline (last available rolling average before the first dose of study drug) and Week 1
- +39 more secondary outcomes
Study Arms (3)
Placebo / Upadacitinib
PLACEBO COMPARATORParticipants will receive placebo orally once a day (QD) for 16 weeks in the double-blind treatment period. At Week 16 participants will be re-randomized to receive either upadacitinib 15 mg or upadacitinib 30 mg QD up to Week 260.
Upadacitinib 15 mg QD
EXPERIMENTALParticipants will receive upadacitinib 15 mg orally once a day for up to 260 weeks.
Upadacitinib 30 mg QD
EXPERIMENTALParticipants will receive upadacitinib 30 mg orally once a day for up to 260 weeks.
Interventions
Tablets taken orally once a day
Eligibility Criteria
You may qualify if:
- Body weight of ≥ 40 kg at Baseline Visit for participants between ≥ 12 and \< 18 years of age
- Chronic atopic dermatitis (AD) with onset of symptoms at least 3 years before Baseline Visit and subject meets Hanifin and Rajka criteria.
- Active moderate to severe AD defined by:
- Eczema Area and Severity Index (EASI) score ≥ 16 at the Screening and Baseline Visits;
- Validated Investigator's Global Assessment (vIGA) score ≥ 3 at the Screening and Baseline Visits;
- ≥ 10% Body surface area (BSA) of AD involvement at the Screening and Baseline Visits;
- Baseline weekly average of daily Worst Pruritus NRS ≥ 4.
- Candidate for systemic therapy or have recently required systemic therapy for AD
- Subject has applied a topical emollient (moisturizer) twice daily for at least 7 days before the Baseline Visit.
- Documented history of inadequate response to topical corticosteroids (TCS) or topical calcineurin inhibitor (TCI) or documented systemic treatment for AD within 6 months before Baseline Visit
You may not qualify if:
- Prior exposure to any Janus kinase (JAK) inhibitor
- Unable or unwilling to discontinue current atopic dermatitis treatments prior to the study
- Requirement of prohibited medications during the study
- Other active skin diseases or skin infections requiring systemic treatment or would interfere with appropriate assessment of atopic dermatitis lesions
- Female subject who is pregnant, breastfeeding, or considering pregnancy during the study
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- AbbVielead
Study Sites (180)
Alliance Dermatology and MOHs /ID# 200375
Phoenix, Arizona, 85032, United States
Clear Dermatology & Aesthetics Center /ID# 201256
Scottsdale, Arizona, 85255-4134, United States
Bakersfield Derma & Skin Cance /ID# 200433
Bakersfield, California, 93309, United States
First OC Dermatology /ID# 201910
Fountain Valley, California, 92708-3701, United States
California Allergy and Asthma Medical Group /ID# 200727
Los Angeles, California, 90025-7014, United States
Allergy & Asthma Associates of Southern California /ID# 200733
Mission Viejo, California, 92691-6410, United States
Dermatology Clinical Trials /ID# 205876
Newport Beach, California, 92660-7853, United States
UC Davis /ID# 203622
Sacramento, California, 95817, United States
Synergy Dermatology /ID# 200842
San Francisco, California, 94132-1909, United States
San Luis Derm and Laser Clinic /ID# 200372
San Luis Obispo, California, 93405, United States
Stanford University /ID# 200440
Stanford, California, 94305, United States
Care Access Research - Walnut Creek /ID# 200940
Walnut Creek, California, 94598-2488, United States
Dermatology Physicians of Connecticut /ID# 200928
Shelton, Connecticut, 06484-6211, United States
Foxhall Research Center /ID# 213682
Washington D.C., District of Columbia, 20016-4300, United States
Duplicate_George Washington Univ Med /ID# 200364
Washington D.C., District of Columbia, 20037, United States
Clearlyderm Dermatology /ID# 208371
Boca Raton, Florida, 33428, United States
Skin Care Research, LLC /ID# 200811
Boca Raton, Florida, 33486-2269, United States
Olympian Clinical Research /ID# 202914
Clearwater, Florida, 33756, United States
Multi-Speciality Research Associates /ID# 213254
Lake City, Florida, 32055-8835, United States
GSI Clinical Research, LLC /ID# 200849
Margate, Florida, 33063, United States
Florida International Rsrch cr /ID# 218507
Miami, Florida, 33173, United States
Tory P Sullivan, MD PA /ID# 200671
North Miami Beach, Florida, 33162-4708, United States
Leavitt Medical Associates of Florida /ID# 200880
Ormond Beach, Florida, 32174, United States
Precision Clinical Research /ID# 209002
Sunrise, Florida, 33351-7311, United States
Integrated Clinical Research LLC /ID# 200900
West Palm Beach, Florida, 33406-6063, United States
Christie Clinic, LLC /ID# 200427
Champaign, Illinois, 61820, United States
Northwestern University Feinberg School of Medicine /ID# 201644
Chicago, Illinois, 60611-2927, United States
Dawes Fretzin, LLC /ID# 200366
Indianapolis, Indiana, 46256, United States
The South Bend Clinic Center /ID# 200371
South Bend, Indiana, 46617, United States
Clinical Trials Management, LLC - Covington /ID# 212658
Covington, Louisiana, 70433, United States
Clinical Trials Management, LLC - Metairie /ID# 212659
Metairie, Louisiana, 70006-4165, United States
Northeast Dermatology /ID# 201338
Beverly, Massachusetts, 01915, United States
Massachusetts General Hospital /ID# 200474
Boston, Massachusetts, 02114, United States
Integrated Dermatology of Massachusetts, LLC /ID# 209468
Quincy, Massachusetts, 02169, United States
Clin Res Inst of Michigan, LLC /ID# 208019
Chesterfield, Michigan, 48047, United States
Henry Ford Medical Center /ID# 204191
Detroit, Michigan, 48202-3046, United States
Cleaver Dermatology /ID# 202825
Kirksville, Missouri, 63501-5362, United States
Advanced Dermatology of the Midlands /ID# 201689
Omaha, Nebraska, 68144-1105, United States
Clinical Research Consortium /ID# 200734
Las Vegas, Nevada, 89119-5190, United States
AllCutis Research Inc /ID# 200981
Portsmouth, New Hampshire, 03801, United States
Forest Hills Dermatology Group /ID# 209244
Kew Gardens, New York, 11415, United States
Icahn School of Medicine at Mount Sinai /ID# 200370
New York, New York, 10029-6504, United States
Montefiore Medical Center /ID# 200456
The Bronx, New York, 10467, United States
J. Schwartz, MD, PLLC /ID# 202121
Troy, New York, 12180-2323, United States
Velocity clinical research /ID# 202653
Cleveland, Ohio, 44122, United States
Lynn Health Science Institute (LHSI) /ID# 212676
Oklahoma City, Oklahoma, 73112, United States
Newton Clinical Research /ID# 204169
Oklahoma City, Oklahoma, 73120-5049, United States
Oregon Medical Res Center PC /ID# 200428
Portland, Oregon, 97223, United States
Oregon Health and Science University /ID# 200992
Portland, Oregon, 97239, United States
Dermdox Dermatology Centers, PC /ID# 213782
Hazleton, Pennsylvania, 18201, United States
Clinical Partners, LLC /ID# 200460
Johnston, Rhode Island, 02919, United States
Coastal Clinical Research Center of the Carolinas /ID# 200402
Charleston, South Carolina, 29414, United States
Arlington Research Center, Inc /ID# 200391
Arlington, Texas, 76011, United States
Orion Clinical Research /ID# 204703
Austin, Texas, 78759-4100, United States
Modern Research Associates, PL /ID# 200705
Dallas, Texas, 75231, United States
Menter Dermatology Res Inst /ID# 200390
Dallas, Texas, 75246, United States
Center for Clinical Studies - Webster TX /ID# 203185
Webster, Texas, 77598, United States
Dermatology Specialists of Spokane /ID# 202068
Spokane, Washington, 99202, United States
Framingham Centro Medico /ID# 202688
La Plata, Buenos Aires, 1902, Argentina
Instituto de Neumonología y Dermatología /ID# 203444
Ciudad Autonoma de Buenos Aire, Ciuadad Autonoma de Buenos Aires, 1425, Argentina
Psoriahue Med Interdisciplinar /ID# 202451
Ciudad Autonoma de Buenos Aire, Ciuadad Autonoma de Buenos Aires, 1425, Argentina
Woden Dermatology /ID# 205799
Phillip, Australian Capital Territory, 2606, Australia
Holdsworth House Medical Practice /ID# 211236
Darlinghurst, New South Wales, 2010, Australia
North Eastern Health Specialists /ID# 205802
Hectorville, South Australia, 5073, Australia
Skin Health Institute Inc /ID# 204791
Carlton, Victoria, 3053, Australia
Fremantle Dermatology /ID# 205305
Fremantle, Western Australia, 6160, Australia
University Clinical Centre of the Republic of Srpska /ID# 202666
Banja Luka, Republika Srpska, 78000, Bosnia and Herzegovina
University Clinical Centre of the Republic of Srpska /ID# 202667
Banja Luka, Republika Srpska, 78000, Bosnia and Herzegovina
Clinical Center University of Sarajevo /ID# 202668
Sarajevo, 71000, Bosnia and Herzegovina
Clinical Center University of Sarajevo /ID# 202669
Sarajevo, 71000, Bosnia and Herzegovina
UMHAT Alexandrovska EAD /ID# 201519
Sofiya, Sofia, 1431, Bulgaria
UMHAT Dr Georgi Stranski EAD /ID# 201521
Pleven, 5800, Bulgaria
UMHAT Professor Stoyan Kirkovich /ID# 201522
Stara Zagora, 6000, Bulgaria
Kirk Barber Research, CA /ID# 200324
Calgary, Alberta, T2G 1B1, Canada
Dermatology Research Institute Inc. /ID# 200318
Calgary, Alberta, T2J 7E1, Canada
Dr. Chih-ho Hong Medical Inc. /ID# 200311
Surrey, British Columbia, V3R 6A7, Canada
Enverus Medical Research /ID# 200307
Surrey, British Columbia, V3V 0C6, Canada
Wiseman Dermatology Research /ID# 200323
Winnipeg, Manitoba, R3M 3Z4, Canada
Dr. Irina Turchin PC Inc. /ID# 200322
Fredericton, New Brunswick, E3B 1G9, Canada
Karma Clinical Trials /ID# 200316
St. John's, Newfoundland and Labrador, A1A 4Y3, Canada
Hamilton Health Sciences - McMaster University Medical Centre /ID# 200313
Hamilton, Ontario, L8S 4K1, Canada
Dr. Wei Jing Loo Medicine Prof /ID# 206051
London, Ontario, N6H 5L5, Canada
Lynderm Research Inc. /ID# 200315
Markham, Ontario, L3P 1X2, Canada
Dermatology Ottawa Research Centre /ID# 200319
Ottawa, Ontario, K2C 3N2, Canada
K. Papp Clinical Research /ID# 200317
Waterloo, Ontario, N2J 1C4, Canada
Innovaderm Research Inc. /ID# 200320
Montreal, Quebec, H2X 2V1, Canada
Dr. David Gratton Dermat Inc. /ID# 200309
Montreal, Quebec, H3H 1V4, Canada
Dre Angelique Gagne-Henley M.D. inc. /ID# 200326
Saint-Jérôme, Quebec, J7Z 7E2, Canada
Peking University People's Hospital /ID# 202549
Beijing, Beijing Municipality, 100044, China
Peking University Third Hospital /ID# 202612
Beijing, Beijing Municipality, 100191, China
Sun Yat-sen Memorial Hospital of Sun Yat-sen University /ID# 208597
Guangzhou, Guangdong, 510120, China
The Third Affiliated Hospital Of Sun Yat-Sen University /ID# 202548
Guangzhou, Guangdong, 510630, China
The First Hospital of China Medical University /ID# 202615
Shenyang, Liaoning, 110001, China
Ruijin Hospital, Shanghai Jiaotong University School of Medicine /ID# 202554
Shanghai, Shanghai Municipality, 200065, China
The second Affiliated hospital of Zhejiang University school of Medicine /ID# 202608
Hangzhou, Zhejiang, 310009, China
Beijing Friendship Hospital /ID# 202601
Beijing, 100032, China
Huashan Hospital of Fudan University /ID# 205760
Shanghai, 200040, China
Union Hospital affiliated to Tongji Medical College of Huazhong University of Sc /ID# 208598
Wuhan, 420022, China
Clinisalud del sur /ID# 218100
Medellín, Antioquia, 055422, Colombia
Fundacion Hospital San Vicente de Paul - Rionegro /ID# 202043
Rionegro, Antioquia, 054040, Colombia
Ctr Int de Reum del Caribe SAS /ID# 201620
Barranquilla, Atlántico, 80002, Colombia
Fundacion Centro de Excelencia en Enfermedades Cronicas no Transmisibles - FUNCE /ID# 201905
Montería, Departamento de Córdoba, 230002, Colombia
Klinicki bolnicki centar Zagreb /ID# 201879
Zagreb, City of Zagreb, 10000, Croatia
Klinika za dječje bolesti Zagreb /ID# 203151
Zagreb, City of Zagreb, 10000, Croatia
Duplicate_Klinicki bolnicki centar Osijek /ID# 201523
Osijek, County of Osijek-Baranja, 31000, Croatia
Klinicki bolnicki centar Rijeka /ID# 217423
Rijeka, Primorje-Gorski Kotar County, 51000, Croatia
Klinicki bolnicki centar Split /ID# 201527
Split, Split-Dalmatia County, 21000, Croatia
Bispebjerg and Frederiksberg Hospital /ID# 200979
Copenhagen NV, Capital Region, 2400, Denmark
Herlev and Gentofte Hospital /ID# 200736
Hellerup, Capital Region, 2900, Denmark
Aarhus University Hospital /ID# 200737
Aarhus N, Central Jutland, 8200, Denmark
North Estonia Medical Centre /ID# 200951
Mustamäe, Harju, 13419, Estonia
Confido Private Medical Clinic /ID# 200846
Tallinn, Harju, 11313, Estonia
Tartu University Hospital /ID# 200847
Tartu, Tartu, 50406, Estonia
Mehiläinen Neo /ID# 201116
Turku, Southwest Finland, 20520, Finland
Kuopio University Hospital /ID# 202449
Kuopio, 70210, Finland
Terveystalo Tampere /ID# 201117
Tampere, 33100, Finland
HCL - Hôpital Lyon Sud /ID# 201529
Pierre-Bénite, Auvergne-Rhône-Alpes, 69495, France
CHU de Nantes, Hotel Dieu -HME /ID# 206377
Nantes, Pays de la Loire Region, 44000, France
Centre Hospitalier du Mans /ID# 205991
Le Mans, Sarthe, 72037, France
Hopital Saint Vincent de Paul /ID# 218253
Lille, 59020, France
Le Bateau BLanc /ID# 206833
Martigues, 13500, France
AP-HP - Hopital Necker /ID# 218364
Paris, 75015, France
Hôpital Charles-Nicolle /ID# 201525
Rouen, 76000, France
CHU Toulouse - Hopital Larrey /ID# 201528
Toulouse, 31400, France
Duplicate_Klinikum rechts der Isar - Technische Universitaet Muenchen /ID# 202087
Munich, Bavaria, 80802, Germany
Universitaetsklinikum Frankfurt /ID# 202089
Frankfurt am Main, Hesse, 60590, Germany
Universitaetsklinikum Muenster /ID# 202085
Münster, North Rhine-Westphalia, 48149, Germany
CMS3 Company for Medical Study /ID# 205193
Selters, Rhineland-Palatinate, 56242, Germany
Universitaetsklinikum Schleswig-Holstein Campus Kiel /ID# 202255
Kiel, Schleswig-Holstein, 24105, Germany
Universitaetsklinikum Bonn /ID# 202086
Bonn, 53127, Germany
TFS Trial Form Support GmbH /ID# 202083
Hamburg, 20537, Germany
Medizinische Hochschule Hannover /ID# 202091
Hanover, 30625, Germany
Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz /ID# 205192
Mainz, 55131, Germany
Fondazione PTV Policlinico Tor Vergata /ID# 201136
Rome, Roma, 00133, Italy
Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona /ID# 200692
Ancona, 60126, Italy
A.O.U. di Bologna Policlinico S.Orsola-Malpighi /ID# 200746
Bologna, 40138, Italy
A.O.U. Policlinico G. Rodolico S.Marco- Presidio G.Rodolico /ID# 200741
Catania, 95123, Italy
Azienda Ospedaliera Universitaria Federico II /ID# 200750
Napoli, 80131, Italy
Azienda Ospedaliero Universitaria Pisana-Stabilimento di Santa Chiara /ID# 200695
Pisa, 56126, Italy
Aichi Medical University Hospital /ID# 202833
Nagakute-shi, Aichi-ken, 480-1195, Japan
Fukuoka University Hospital /ID# 201309
Fukuoka, Fukuoka, 814-0180, Japan
Kyushu Central Hospital of the Mutual Aid Association of Public School Teachers /ID# 202891
Fukuoka, Fukuoka, 815-8588, Japan
Gifu University Hospital /ID# 201760
Gifu, Gifu, 501-1194, Japan
Ogaki Municipal Hospital /ID# 203463
Ogaki-shi, Gifu, 503-8502, Japan
Takagi Dermatology Clinic /ID# 201238
Obihiro-shi, Hokkaido, 080-0013, Japan
Medical Cooperation Kojinkai Sapporo Skin Clinic /ID# 201239
Sapporo, Hokkaido, 060-0063, Japan
University Hospital Kyoto Prefectural University of Medicine /ID# 201876
Kyoto, Kyoto, 602-8566, Japan
Kume Clinic /ID# 201912
Sakai-shi, Osaka, 5938324, Japan
NTT Medical Center Tokyo /ID# 201759
Shinagawa-ku, Tokyo, 141-8625, Japan
University of Yamanashi Hospital /ID# 204174
Chuo-shi, Yamanashi, 409-3821, Japan
Hospital Raja Permaisuri Bainun /ID# 204375
Ipoh, Perak, 30450, Malaysia
Queen Elizabeth Hospital /ID# 204379
Division Pantai Barat Utara, Sabah, 88200, Malaysia
Hospital Selayang /ID# 204378
Batu Caves, Selangor, 68100, Malaysia
Clinical Trials NZ /ID# 205335
Hamilton, 3204, New Zealand
Cruz-Santana, Carolina, PR /ID# 201096
Carolina, 00985, Puerto Rico
Ponce Medical School Foundation /ID# 201821
Ponce, 00716-0377, Puerto Rico
Clinical Research Puerto Rico /ID# 203309
San Juan, 00909, Puerto Rico
Spitalul Clinic Colentina /ID# 205860
Bucharest, 020121, Romania
Cabinet Medical de Dermatovenerologie Dr. Remus Orasan /ID# 205862
Cluj-Napoca, 400105, Romania
Chelyabinsk Regional Clinical Dermatovenerologic Dispensary /ID# 201996
Chelyabinsk, Chelyabinsk Oblast, 454048, Russia
Clinical Dermatovenerology Dispensary /ID# 203439
Krasnodar, Krasnodarskiy Kray, 350020, Russia
Saratov State Medical University n.a. V.I. Razumovskiy /ID# 201595
Saratov, Saratov Oblast, 410012, Russia
Ural Research Institute of dermatovenerology and immunopathology /ID# 201593
Yekaterinburg, Sverdlovsk Oblast, 620076, Russia
National Medical Research Center for Children's Health /ID# 203440
Moscow, 119296, Russia
Universitätsspital Basel /ID# 201599
Basel, Canton of Basel-City, 4031, Switzerland
Hôpitaux Universitaires Genève /ID# 201600
Geneva, Canton of Geneva, 1205, Switzerland
CHUV, Centre hospitalier universitaire vaudois /ID# 200910
Lausanne, Canton of Vaud, 1011, Switzerland
CHUV, Centre hospitalier universitaire vaudois /ID# 206505
Lausanne, Canton of Vaud, 1011, Switzerland
Inselspital, Universitätsspital Bern /ID# 201598
Bern, 3010, Switzerland
Erciyes University Medical Fac /ID# 204098
Melikgazi, Kayseri, 38030, Turkey (Türkiye)
Hacettepe University Faculty of Medicine /ID# 204099
Ankara, 06100, Turkey (Türkiye)
Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty /ID# 204100
Istanbul, 34098, Turkey (Türkiye)
Gazi Universitesi Tip Fakultes /ID# 204176
Yenimahalle, 06560, Turkey (Türkiye)
Military Hospital of Military-Medical Clinical Center of Southern Region /ID# 201962
Zaporizhzhya, Zaporizhzhia Oblast, 69063, Ukraine
ME "Rivne Regional Dermatology and Venereology Dispensary" of RRC /ID# 210504
Rivne, 33028, Ukraine
West Middlesex University Hospital /ID# 202273
Isleworth, London, City of, TW7 6AF, United Kingdom
Barts Health NHS Trust /ID# 201043
London, London, City of, E1 2ES, United Kingdom
Guy's and St Thomas' NHS Foundation Trust /ID# 201192
London, London, City of, SE1 9RT, United Kingdom
Chelsea and Westminster Hospital NHS Foundation Trust9 /ID# 201971
London, SW10 9NH, United Kingdom
Northern Care Alliance NHS Group /ID# 201194
Salford, M6 8HD, United Kingdom
Related Publications (13)
Irvine AD, Prajapati VH, Guttman-Yassky E, Simpson EL, Papp KA, Blauvelt A, Chu CY, Hong HC, Gold LFS, de Bruin-Weller M, Bieber T, Kabashima K, Rosmarin D, Sancho C, Calimlim BM, Grada A, Yang Y, Wu X, Levy G, Raymundo EM, Teixeira HD, Silverberg JI. Efficacy and Safety of Upadacitinib in Patients With Moderate-to-Severe Atopic Dermatitis: Phase 3 Randomized Clinical Trial Results Through 140 Weeks. Am J Clin Dermatol. 2025 Nov;26(6):1003-1016. doi: 10.1007/s40257-025-00975-3. Epub 2025 Sep 3.
PMID: 40900410DERIVEDBurmester GR, Deodhar A, Irvine AD, Panaccione R, Winthrop KL, Vleugels RA, Levy G, Suravaram S, Palac H, Wegrzyn L, Ford S, Meerwein S, Guttman-Yassky E. Safety Profile of Upadacitinib: Descriptive Analysis in Over 27,000 Patient-Years Across Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis, Atopic Dermatitis, and Inflammatory Bowel Disease. Adv Ther. 2025 Oct;42(10):5215-5237. doi: 10.1007/s12325-025-03328-y. Epub 2025 Aug 28.
PMID: 40875187DERIVEDSimpson EL, Silverberg JI, Prajapati VH, Eyerich K, Katoh N, Boguniewicz M, Guttman-Yassky E, Song EJ, Lee WJ, Teixeira HD, Wu T, Sancho Sanchez C, Vigna N, Calimlim BM, de Bruin-Weller M. Rapid Itch Improvement and Skin Clearance with Upadacitinib Versus Placebo (Measure Up 1 and Measure Up 2) and Versus Dupilumab (Heads Up): Results from Three Phase 3 Clinical Trials in Patients with Moderate-to-Severe Atopic Dermatitis. Dermatol Ther (Heidelb). 2025 Aug;15(8):2061-2076. doi: 10.1007/s13555-025-01443-w. Epub 2025 Jun 2.
PMID: 40457140DERIVEDPaller AS, Mendes-Bastos P, Siegfried E, Eichenfield LF, Soong W, Prajapati VH, Lio P, Simpson EL, Raymundo EM, Suravaram S, Hu X, Yang Y, Huang X, Calimlim BM, Platt AM, Su JC, Zheng M, Yamamoto-Hanada K, Teixeira HD, Irvine AD. Upadacitinib in Adolescents With Moderate to Severe Atopic Dermatitis: Analysis of 3 Phase 3 Randomized Clinical Trials Through 76 Weeks. JAMA Dermatol. 2024 Dec 1;160(12):1304-1313. doi: 10.1001/jamadermatol.2024.3696.
PMID: 39441580DERIVEDBlauvelt A, Eyerich K, Irvine AD, de Bruin-Weller M, Kwatra SG, Gooderham M, Kim B, Calimlim BM, Lee WJ, Raymundo EM, Liu Y, Ofori S, Platt AM, Silverberg JI. More Time Spent with Clear Skin and No Itch with Upadacitinib versus Dupilumab for Atopic Dermatitis. Dermatol Ther (Heidelb). 2024 Sep;14(9):2621-2630. doi: 10.1007/s13555-024-01242-9. Epub 2024 Aug 7.
PMID: 39110139DERIVEDSimpson EL, Prajapati VH, Leshem YA, Chovatiya R, de Bruin-Weller MS, Stander S, Pink AE, Calimlim BM, Lee WJ, Teixeira H, Ladizinski B, Hu X, Yang Y, Liu Y, Liu M, Grada A, Platt AM, Silverberg JI. Upadacitinib Rapidly Improves Patient-Reported Outcomes in Atopic Dermatitis: 16-Week Results from Phase 3 Clinical Trials (Measure Up 1 and 2). Dermatol Ther (Heidelb). 2024 May;14(5):1127-1144. doi: 10.1007/s13555-024-01157-5. Epub 2024 May 2.
PMID: 38696027DERIVEDSilverberg JI, Gooderham MJ, Paller AS, Deleuran M, Bunick CG, Gold LFS, Hijnen D, Calimlim BM, Lee WJ, Teixeira HD, Hu X, Zhang S, Yang Y, Grada A, Platt AM, Thaci D. Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2). Am J Clin Dermatol. 2024 May;25(3):485-496. doi: 10.1007/s40257-024-00853-4. Epub 2024 Mar 25.
PMID: 38528257DERIVEDThyssen JP, Thaci D, Bieber T, Gooderham M, de Bruin-Weller M, Soong W, Kabashima K, Barbarot S, Luna PC, Xu J, Hu X, Liu Y, Raymundo EM, Calimlim BM, Nduaka C, Gamelli A, Simpson EL. Upadacitinib for moderate-to-severe atopic dermatitis: Stratified analysis from three randomized phase 3 trials by key baseline characteristics. J Eur Acad Dermatol Venereol. 2023 Sep;37(9):1871-1880. doi: 10.1111/jdv.19232. Epub 2023 Jun 21.
PMID: 37247226DERIVEDPaller AS, Ladizinski B, Mendes-Bastos P, Siegfried E, Soong W, Prajapati VH, Lio P, Thyssen JP, Simpson EL, Platt AM, Raymundo EM, Liu J, Calimlim BM, Huang X, Gu Y, Hu X, Yang Y, Su JC, Zheng M, Yamamoto-Hanada K, Teixeira HD, Irvine AD. Efficacy and Safety of Upadacitinib Treatment in Adolescents With Moderate-to-Severe Atopic Dermatitis: Analysis of the Measure Up 1, Measure Up 2, and AD Up Randomized Clinical Trials. JAMA Dermatol. 2023 May 1;159(5):526-535. doi: 10.1001/jamadermatol.2023.0391.
PMID: 37043227DERIVEDBurmester GR, Cohen SB, Winthrop KL, Nash P, Irvine AD, Deodhar A, Mysler E, Tanaka Y, Liu J, Lacerda AP, Palac H, Shaw T, Mease PJ, Guttman-Yassky E. Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis. RMD Open. 2023 Feb;9(1):e002735. doi: 10.1136/rmdopen-2022-002735.
PMID: 36754548DERIVEDMendes-Bastos P, Ladizinski B, Guttman-Yassky E, Jiang P, Liu J, Prajapati VH, Simpson EL, Vigna N, Teixeira HD, Barbarot S. Characterization of acne associated with upadacitinib treatment in patients with moderate-to-severe atopic dermatitis: A post hoc integrated analysis of 3 phase 3 randomized, double-blind, placebo-controlled trials. J Am Acad Dermatol. 2022 Oct;87(4):784-791. doi: 10.1016/j.jaad.2022.06.012. Epub 2022 Jun 15.
PMID: 35714786DERIVEDSimpson EL, Papp KA, Blauvelt A, Chu CY, Hong HC, Katoh N, Calimlim BM, Thyssen JP, Chiou AS, Bissonnette R, Stein Gold LF, Wegzyn C, Hu X, Liu M, Liu J, Tenorio AR, Chu AD, Guttman-Yassky E. Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis: Analysis of Follow-up Data From the Measure Up 1 and Measure Up 2 Randomized Clinical Trials. JAMA Dermatol. 2022 Apr 1;158(4):404-413. doi: 10.1001/jamadermatol.2022.0029.
PMID: 35262646DERIVEDGuttman-Yassky E, Teixeira HD, Simpson EL, Papp KA, Pangan AL, Blauvelt A, Thaci D, Chu CY, Hong HC, Katoh N, Paller AS, Calimlim B, Gu Y, Hu X, Liu M, Yang Y, Liu J, Tenorio AR, Chu AD, Irvine AD. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet. 2021 Jun 5;397(10290):2151-2168. doi: 10.1016/S0140-6736(21)00588-2. Epub 2021 May 21.
PMID: 34023008DERIVED
Related Links
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Results Point of Contact
- Title
- Global Medical Services
- Organization
- AbbVie
Study Officials
- STUDY DIRECTOR
ABBVIE INC.
AbbVie
Publication Agreements
- PI is Sponsor Employee
- No
- Restriction Type
- OTHER
- Restrictive Agreement
- Yes
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- QUADRUPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
- Expanded Access
- Yes
Study Record Dates
First Submitted
June 14, 2018
First Posted
June 26, 2018
Study Start
August 13, 2018
Primary Completion
January 6, 2021
Study Completion
October 10, 2025
Last Updated
October 24, 2025
Results First Posted
February 3, 2022
Record last verified: 2025-10
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP, CSR
- Time Frame
- Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.
- Access Criteria
- Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.
AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.